DarioHealth reports Q1 EPS (14c), consensus (5c)

Reports Q1 revenue $6.75M, consensus $7.47M. “We are building a business that is fully aligned with the most important trends in healthcare,” said Erez Raphael, CEO of Dario. “From the expansion of GLP-1 therapies beyond weight loss into chronic condition management, to the scalability unlocked by AI and the market shift towards integrated, multi-condition solutions, we believe that our platform and our strategy are uniquely positioned at the convergence of these trends. We believe that our commercial wins, cost reductions, and continued product innovation reflect that alignment and move us closer to predictable, sustainable growth with high-quality revenue streams.”